Edinburgh-based health tech company Concinnity Genetics has closed an overscribed funding round worth £3m.

Founded in 2023, Concinnity Genetics is a spinout developing novel gene therapies with control mechanisms.

“Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible,” said Jessica Birt, CEO and co-founder of Concinnity.

“This commitment from our investors, building on the ongoing support from Scottish Enterprise, speaks to the potential they see in our work, and we look forward to using the funding to further develop our technology.”

The funding round was led by Scottish investor Eos Advisory.

“Concinnity is a perfect fit for Eos’s focus on backing pioneering Scottish science, addressing a significant unmet need in gene therapy,” said Eos managing partner Andrew McNeill.

“By combining synthetic biology and AI-machine learning, the Concinnity technology has been described as the ‘holy grail for emerging gene therapies’, making such treatments both more effective and safer.”

Additional funding came from Scottish Enterprise, Old College Capital – the University of Edinburgh’s in-house venture investment fund, and Maven Capital Partners.

“Engineering biology is a major strength of the University of Edinburgh, catalysing novel solutions across our three mission areas of future health and care, data and AI for good, and climate and sustainability,” said Dr Andrea Taylor, CEO of Edinburgh Innovations, the University of Edinburgh’s commercialisation service.

“Sophisticated gene control systems have the potential to revolutionise advanced therapeutics, enabling new kinds of treatments that will impact future health.”

Already have an account? Log in